文献速递淋巴瘤造血干细胞移植与细胞治疗

自体造血干细胞移植治疗T淋巴母细胞淋巴瘤

[Autologous hematopoietic stem cell transplantation treatment for T cell lymphoblastic lymphoma].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2020-01-01

回顾性分析41例接受auto-HSCT的T-LBL患者,中位随访29个月,3年OS率、PFS率分别为(64.3±8.2)%、(66.0±7.8)%。移植前CR(1)状态和IPI评分是影响生存的重要因素。

要点

  • 41例T-LBL患者auto-HSCT后3年OS率为(64.3±8.2)%,3年PFS率为(66.0±7.8)%。
  • CR(1)组3年OS率(83.4±7.6)%高于非CR(1)组(38.9±12.9)%(P=0.010)。
  • IPI中低危组3年OS率(76.9±8.4)%高于中高危组(35.7±15.2)%(P=0.014)。

核心结论

  • auto-HSCT可改善T-LBL患者的生存,移植前疾病状态和IPI评分是影响auto-HSCT疗效的重要因素。

研究设计与样本

  • 回顾性分析2006年4月至2017年7月在苏州大学附属第一医院血液科和北京大学肿瘤医院淋巴瘤科接受auto-HSCT的41例T-LBL患者。

主要发现

  • 41例患者中男30例、女11例,中位年龄24(11~53)岁,Ann Arbor分期Ⅲ/Ⅳ期33例(80.5%),纵隔累及12例(29.3%),骨髓累及20例(48.8%)。
  • 移植前CR(1)期26例(63.4%),非CR(1)期15例(36.6%);IPI中低危组(<3分)29例(70.7%),中高危组(≥3分)12例(29.3%)。
  • 中位随访29(3~98)个月,全部41例3年OS率为(64.3±8.2)%,3年PFS率为(66.0±7.8)%,3年CIR为(30.7±7.4)%,3年NRM为(4.8±4.6)%。
  • CR(1)组与非CR(1)组3年OS率分别为(83.4±7.6)%和(38.9±12.9)%(P=0.010),3年PFS率分别为(83.8±7.4)%和(40.0±12.6)%(P=0.006),3年CIR分别为(16.2±7.4)%和(53.3±12.9)%(P=0.015),3年NRM分别为0和(14.3±13.2)%(P=0.157)。
  • IPI中低危组与中高危组3年OS率分别为(76.9±8.4)%和(35.7±15.2)%(P=0.014),3年PFS率分别为(77.4±8.2)%和(40.0±14.6)%(P=0.011),3年CIR分别为(18.1±7.3)%和(60.0±14.6)%(P=0.006),3年NRM分别为(5.6±5.4)%和0(P=0.683)。

临床怎么用

  • 原文结论为auto-HSCT可改善T-LBL患者的预后,移植前疾病状态和IPI评分是影响auto-HSCT疗效的重要因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the efficacy and predictors of autologous hematopoietic stem cell transplantation (auto-HSCT) in the treatment of T lymphoblastic lymphoma (T-LBL) . Methods: 41 patients with T-LBL who underwent auto-HSCT from April 2006 to July 2017 in the Department of Hematology, the First Affiliated Hospital of Soochow University and the Department of Lymphoma, Peking University Cancer Hospital were analyzed retrospectively. Results: ①Among 41 patients, there were 30 males and 11 females with median age of 24 (11-53) years old. According to the Ann Arbor staging, 33 (80.5%) patients were in stage Ⅲ/Ⅳ. 12 (29.3%) patients have mediastinal involvement, and 20 (48.8%) patients have bone marrow (BM) involvement. Before transplantation, there were 26 (63.4%) patients who achieved first complete remission (CR(1)) , the other 15 (36.6%) patients were in the non-CR(1) group, and there were 29 (70.7%) patients in the low-intermediate risk group (IPI<3 scores) , the other 12 (34.1%) patients were in the middle-high risk group (IPI≥3 scores) . ②The median follow-up was 29 (3-98) months. The 3-year overall survival (OS) and progression-free survival (PFS) for 41 patients were (64.3±8.2) % and (66.0±7.8) %, respectively. 3-year cumulative recurrence rate (CIR) was (30.7±7.4) %, and 3-year non-recurring mortality (NRM) was (4.8±4.6) %. ③The 3-year OS of the CR(1) group and the non-CR(1) group were (83.4±7.6) % and (38.9±12.9) % (P=0.010) , and the 3-year PFS of two groups were (83.8±7.4) % and (40.0±12.6) % (P=0.006) , respectively. The 3-year CIR of these two groups were (16.2±7.4) % and (53.3±12.9) % (P=0.015) , and the 3-year NRM were 0 and (14.3±13.2) % (P=0.157) , respectively. ④The 3-year OS of the IPI low-intermediate risk group and the high-intermediate risk group were (76.9±8.4) % and (35.7±15.2) % (P=0.014) and the 3-year PFS were (77.4±8.2) % and (40.0±14.6) (P=0.011) , respectively. The 3-year CIR of these two groups were (18.1±7.3) % and (60.0±14.6) % (P=0.006) , and the 3-year NRM were (5.6±5.4) % and 0 (P=0.683) , respectively. The OS and PFS of patients with low-intermediate risk group were significantly higher than the other group. Conclusion: Auto-HSCT could improve the survival of T-LBL. Pre-transplant status and IPI score are important predictors for survival T-LBL patients with auto-HSCT. 目的: 探讨自体造血干细胞移植(auto-HSCT)巩固治疗T淋巴母细胞淋巴瘤(T-LBL)的疗效及相关影响因素。 方法: 对2006年4月至2017年7月在苏州大学附属第一医院血液科和北京大学肿瘤医院淋巴瘤科接受auto-HSCT的41例T-LBL患者进行回顾性分析。 结果: ①41例T-LBL患者中,男30例,女11例,中位年龄24(11~53)岁,12例(29.3%)纵隔累及,20例(48.8%)骨髓累及,Ann Arbor分期Ⅲ期及以上33例(80.5%);移植前疾病处于第1次完全缓解(CR(1))期26例(63.4%),非CR(1)期15例(36.6%);移植前国际预后指数(IPI)中低危组(<3分)29例(70.7%),中高危组(≥3分)12例(29.3%)。②移植后中位随访29(3~98)个月,全部41例患者的3年总生存(OS)率、无进展生存(PFS)率分别为(64.3±8.2)%、(66.0±7.8)%,3年累积复发率(CIR)为(30.7±7.4)%,3年非复发死亡率(NRM)为(4.8±4.6)%。③CR(1)组、非CR(1)组患者3年OS率分别为(83.4±7.6)%、(38.9±12.9)%(P=0.010),3年PFS率分别为(83.8±7.4)%、(40.0±12.6)%(P=0.006),3年CIR分别为(16.2±7.4)%、(53.3±12.9)%(P=0.015),3年NRM分别为0、(14.3±13.2)%(P=0.157)。④IPI中低危组、中高危组3年OS率分别为(76.9±8.4)%、(35.7±15.2)%(P=0.014),3年PFS率分别为(77.4±8.2)%、(40.0±14.6)%(P=0.011),3年CIR分别为(18.1±7.3)%、(60.0±14.6)%(P=0.006),3年NRM分别为(5.6±5.4)%、0(P=0.683)。 结论: auto-HSCT可显著改善T-LBL患者的预后,移植前疾病状态和IPI评分是影响auto-HSCT疗效的重要因素。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang P, Li CX, Zhang Y, et al. [Autologous hematopoietic stem cell transplantation treatment for T cell lymphoblastic lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 32311888. doi:10.3760/cma.j.issn.0253-2727.2020.03.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。